CSTL
Castle Biosciences, Inc.
Diagnostics & Research · Healthcare · United States
37.16
close · 2026-10-30
value
55
cheaper than peers55
quality
74
stronger fundamentals74
ranked against
Diagnostics & Research
value
quality
31 peers
Value inputs
| measure | company | vs peers |
| cash flow yield, 1 year ago | 3.2% | 85 |
| price to book | 2.41× | 84 |
| earnings yield, 1 year ago | 1.7% | 69 |
| cash flow yield, latest year | 2.5% | 66 |
| price to sales | 3.18× | 63 |
| cash flow yield, 2 years ago | -1.7% | 34 |
| earnings yield, 2 years ago | -5.8% | 34 |
| cash flow yield, 3 years ago | -4.2% | 34 |
| earnings yield, 3 years ago | -6.9% | 28 |
| earnings yield, latest year | -2.2% | 27 |
10 of 12 measures available
Quality inputs
| measure | company | vs peers |
| debt to equity | 7.8% | 88 |
| revenue growth | 20.1% | 69 |
| return on equity | -4.2% | 47 |
| operating margin | -3.0% | 45 |
4 of 4 measures available
Facts
| market cap | $1B |
| free cash flow | -$7.3M |
| employees | 1,002 |
| first trade | 2019-07-25 |
| next earnings | 2026-11-05 |
| fundamentals updated | 2026-08-05 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -0.83 | 0.62 | -2.14 | -2.58 |
| free cash flow | $28.3M | $36.5M | -$19.2M | -$47.3M |
| net income | -$24.2M | $18.2M | -$57.5M | -$67.1M |
| revenue | $344.2M | $332.1M | $219.8M | $137.0M |
| unusual items | $1.5M | $555,000 | $0 | $18.3M |